PROGNOSTIC SIGNIFICANCE OF CD44 EXPRESSION IN COLON ADENOCARCINOMA
Background. The risk of developing colorectal cancer is 5-6%, i.e., every 20th person develops cancer of this localization during a lifetime. A lot of works are devoted to the study of molecular markers for diagnosis and prognosis of tumors, especially at a young age. CD44 is one of these markers, but data on its role in predicting the course of colorectal cancer are contradictory. Objective - determine the prognostic role of the CD44 positivity level in colon adenocarcinoma. Material and methods. A clinical and morphological analysis of 61 cases of colon adenocarcinoma was investigated. Immunohistochemical study was performed using mouse monoclonal antibodies to CD44. Marker expression was quantified using the computer program Aperio Image Scope_v9.1.19.1567. Statistical analysis was performed using STATISTICA 10.0 (SNAXAR207F394425FA-Q). Results. It was found that the level of CD44 in tumor tissue is significantly higher than at the margins of resection. At the same time, expression in the stroma of the tumor is significantly higher than in tumor proliferates. There were no statistically significant differences in the positivity of CD44 depending on sex, tumor location, degree of differentiation, depth of invasion and metastasis. The level of CD44 was determined to predict the survival of middle-aged patients. Conclusion. If the level of parenchymal positivity of CD44 is equal to or below 0.284 with a sensitivity of 100% and a specificity of 80%, it can be predicted that the adjusted disease-free survival of middle-aged patients with colon adenocarcinoma will be more than 3 years.